Current Report Filing (8-k)
April 03 2020 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
April 3, 2020
Date of Report (Date of earliest event reported)
Aprea Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-39069
|
84-2246769
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
535 Boylston Street
Boston, Massachusetts
(Address of principal executive offices)
|
02116
(Zip Code)
|
|
|
|
|
Registrant's telephone number, including area code: (617) 463-9385
(Former name or former address, if changed since last report): Not applicable
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on
which registered
|
Common stock, par value $0.001 per share
|
|
APRE
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01 Other Events
The Board of Directors of Aprea Therapeutics,
Inc. (the “Company”) has determined that, subject to any adjournments or postponements, the Company’s first annual
meeting of stockholders (the “2020 Annual Meeting”) is expected to be held on Friday, June 26, 2020, commencing at
9:00 a.m. Eastern Time. A proxy statement with information regarding the business and voting procedures for the 2020 Annual Meeting
will be distributed to stockholders prior to the meeting.
Deadline for Rule 14a-8 Stockholder Proposals
Under the Securities and Exchange Commission’s
proxy rules, the Company has set the deadline for submission of proposals to be included in the proxy materials for the 2020 Annual
Meeting. Accordingly, in order for a stockholder proposal to be considered for inclusion in the Company’s proxy materials
for the 2020 Annual Meeting, the proposal must be received by the Company’s Secretary at Aprea Therapeutics, Inc., 535 Boylston
Street, Boston, MA 02116 on or before April 13, 2020, and comply with the procedures and requirements set forth in Rule 14a-8 under
the Securities Exchange Act of 1934.
Advance Notice Deadline for Director Nominations and Other
Stockholder Proposals
In accordance with the Company’s Amended
and Restated Bylaws (the “Bylaws”), for director nominations or stockholder proposals to be brought before the upcoming
annual meeting of stockholders, other than Rule 14a-8 proposals described above, written notice must be delivered no later than
April 13, 2020 by mailing such proposals to Aprea Therapeutics, Inc., 535 Boylston Street, Boston, MA 02116, Attn: Corporate Secretary.
Such notices must also comply with the requirements of the Bylaws and other applicable law.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Aprea Therapeutics, Inc.
|
|
|
Dated: April 3, 2020
|
By:
|
/s/ Christian S. Schade
|
|
Name:
|
Christian S. Schade
|
|
Title:
|
President and Chief Executive Officer
|
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Apr 2023 to Apr 2024